Fund Elahere nationally

AI summary

Petitioners ask the Minister of Health to direct the pCPA to resume negotiations with AbbVie and secure national public funding so Elahere becomes a funded treatment for ovarian, fallopian tube and peritoneal cancers.

AI summaries describe petitioners’ requests and claims. Consult the official record for the full text.

Official petition

Petition to the Minister of Health The public funding negotiations for Elahere (mirvetuximab soravtansine) have experienced extensive delays, after initial negotiations concluding with no agreement; In treating ovarian cancer, Elahere has been proven to be more effective than traditional funded chemotherapies (see study in the New England Journal of Medicine); Elahere has side effects that are different from traditionally used chemotherapies, which make it a better choice for many patients with underlying conditions, like Crohn's Disease; and Exorbitant medication costs unfairly disadvantage vulnerable communities, cutting them off from life-changing care. Citizens deserve a healthcare system that funds the most effective treatments available. We, the undersigned, citizens of Canada, call upon the Minister of Health to instruct the pCPA (Pan-Canadian Pharmaceutical Alliance) to restart negotiations with the manufacturer of Elahere (AbbVie), with a mandate of reaching an agreement that will see Elahere become a funded treatment option for patients suffering from ovarian, fallopian tube and peritoneal cancers, across the country.

Government response

No government response is available yet.